2023
Metastasising ameloblastoma or ameloblastic carcinoma? A case report with mutation analyses
HURNÍK, Pavel, Barbora MOLDOVAN PUTNOVA, Tereza SEVCIKOVA, Eva HRUBA, Iveta PUTNOVA et. al.Základní údaje
Originální název
Metastasising ameloblastoma or ameloblastic carcinoma? A case report with mutation analyses
Autoři
HURNÍK, Pavel (203 Česká republika, domácí), Barbora MOLDOVAN PUTNOVA, Tereza SEVCIKOVA (203 Česká republika), Eva HRUBA (203 Česká republika), Iveta PUTNOVA (203 Česká republika), Josef SKARDA (203 Česká republika), Martin HAVEL (203 Česká republika), Oldrich RES (203 Česká republika), Jakub CVEK (203 Česká republika), Marcela BUCHTOVÁ (203 Česká republika) a Jan ŠTEMBÍREK (203 Česká republika)
Vydání
BMC Oral Health, London, BMC, 2023, 1472-6831
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30208 Dentistry, oral surgery and medicine
Stát vydavatele
Velká Británie a Severní Irsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 2.900 v roce 2022
Kód RIV
RIV/00216224:14110/23:00134701
Organizační jednotka
Lékařská fakulta
UT WoS
001048263200004
Klíčová slova anglicky
Ameloblastoma; Carcinoma; Case report; Metastasizing; Malignant; Benign; Wnt pathway; BRAF; FANCA
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 29. 1. 2024 15:01, Mgr. Tereza Miškechová
Anotace
V originále
BackgroundAmeloblastic carcinoma and metastasising ameloblastoma are rare epithelial odontogenic tumours with aggressive features. Distinguishing between these two lesions is often clinically difficult but necessary to predict tumour behaviour or to plan future therapy. Here, we provide a brief review of the literature available on these two types of lesions and present a new case report of a young man with an ameloblastoma displaying metastatic features. We also use this case to illustrate the similarities and differences between these two types of tumours and the difficulties of their differential diagnosis.Case presentationOur histopathological analyses uncovered a metastasising tumour with features of ameloblastic carcinoma, which developed from the ameloblastoma. We profiled the gene expression of Wnt pathway members in ameloblastoma sample of this patient, because multiple molecules of this pathway are involved in the establishing of cell polarity, cell migration or for epithelial-mesenchymal transition during tumour metastasis to evaluate features of tumor behaviour. Indeed, we found upregulation of several cell migration-related genes in our patient. Moreover, we uncovered somatic mutation BRAF p.V600E with known pathological role in cancerogenesis and germline heterozygous FANCA p.S858R mutation, whose interpretation in this context has not been discussed yet. ConclusionsIn conclusion, we have uncovered a unique case of ameloblastic carcinoma associated with an alteration of Wnt signalling and the presence of BRAF mutation. Development of harmful state of our patient might be also supported by the germline mutation in one FANCA allele, however this has to be confirmed by further analyses.
Návaznosti
NU20-08-00205, projekt VaV |
|